Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents
Open Access
- 1 May 2021
- journal article
- research article
- Published by Elsevier BV in Journal of Infection and Public Health
- Vol. 14 (5), 611-619
- https://doi.org/10.1016/j.jiph.2021.01.016
Abstract
No abstract availableFunding Information
- King Saud University
This publication has 34 references indexed in Scilit:
- Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study GroupJournal of Virology, 2013
- The VSGB 2.0 model: A next generation energy model for high resolution protein structure modelingProteins, 2011
- Protection of cellular DNA from γ-radiation-induced damages and enhancement in DNA repair by troxerutinMolecular and Cellular Biochemistry, 2005
- Metabolic and Pharmacological Properties of Rutin, a Dietary Quercetin Glycoside, for Treatment of Inflammatory Bowel DiseasePharmaceutical Research, 2005
- Troxerutin protects the isolated perfused rat liver from a possible lipid peroxidation by coumarinPhytomedicine, 2005
- Treatment of the common cold with troxerutinAPMIS, 2004
- Epidemiologic Clues to SARS Origin in ChinaEmerging Infectious Diseases, 2004
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003
- Nosé-Hoover chain method for nonequilibrium molecular dynamics simulationPhysical Review E, 2000
- Constant pressure molecular dynamics algorithmsThe Journal of Chemical Physics, 1994